Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs) or alcohol are the most common causes. Other causes include stress (secondary to mucosal ischemia) and autoimmune gastritis. Rare forms include phlegmonous gastritis (a rare bacterial infection).
Diagnosis is based on clinical history and characteristic histologic findings. A variety of methods may be used to diagnose H pylori infection.
Presence of suspicious features suggestive of upper gastrointestinal (GI) malignancy requires urgent endoscopy under appropriate clinical conditions. These include GI bleeding, anemia, early satiety, unexplained weight loss (>10% body weight), progressive dysphagia, odynophagia, or persistent vomiting.
Treatment depends on the etiology. Options include H pylori -eradication therapy, reduction of NSAIDs or alcohol exposure, and symptomatic therapy with H₂ antagonists and/or proton-pump inhibitors.
If untreated, progression to peptic ulcer disease may occur. Other complications of some forms of gastritis include gastric carcinoma and gastric lymphoma.
Helicobacter pylori infection may cause both an acute and chronic gastritis.  Erosive gastritis may occur in response to nonsteroidal anti-inflammatory drugs (NSAIDs)/alcohol use or misuse    and to bile reflux into the stomach that may follow previous gastric surgery or cholecystectomy.     Stress gastritis, most commonly related to mucosal ischemia seen in critically ill patients, represents a continuum of disease ranging from superficial (erosions) to deep mucosal damage known as stress ulceration.  Autoimmune gastritis is a diffuse form of mucosal atrophy characterized by autoantibodies to parietal cells and intrinsic factor resulting in inflammatory infiltration and atrophy of the corpus mucosa.   Phlegmonous gastritis is a rare but life-threatening infection of the gastric submucosa and muscularis propria seen in immunocompromised patients.    
Professor of Medicine
Rosalind Franklin University Medical School
North Chicago, Illinois
Adjunct Professor of Pediatric Gastroenterology
University of Miami Miller Medical School
Associate Director for Research
Internal Medicine Residency
Advocate Lutheran General Hospital
Park Ridge, Illinois
EDE declares that he is a consultant for Pediatric Pharmaceuticals.
Dr Eli D. Ehrenpreis would like to gratefully acknowledge Dr Nicole Marie Gentile, Dr Parakkal Deepak, and Dr Elad Eichenwald, previous contributors to this topic. NMG, PD, and EE declare that they have no competing interests.
Professor and Consultant Gastroenterologist
Department of Gastroenterology
Leeds General Infirmary
AA is the author of studies referenced in this topic.
Assistant Professor of Medicine
Section of Gastroenterology and Nutrition
Rush University Medical Center
GS declares that he has no competing interests.
Use of this content is subject to our disclaimer